Celularity Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.57
- Today's High:
- $0.64
- Open Price:
- $0.63
- 52W Low:
- $0.567
- 52W High:
- $13.186
- Prev. Close:
- $0.599
- Volume:
- 163800
Company Statistics
- Market Cap.:
- $90.60 million
- Book Value:
- 1.136
- Revenue TTM:
- $18.70 million
- Operating Margin TTM:
- -760.66%
- Gross Profit TTM:
- $11.68 million
- Profit Margin:
- -76.37%
- Return on Assets TTM:
- -20.08%
- Return on Equity TTM:
- -10.97%
Company Profile
Celularity Inc had its IPO on 2019-08-08 under the ticker symbol CELU.
The company operates in the Healthcare sector and Biotechnology industry. Celularity Inc has a staff strength of 225 employees.
Stock update
Shares of Celularity Inc opened at $0.63 at the start of the last trading session i.e. 2023-03-25.
The stocks traded within a range of $0.57 - $0.64, and closed at $0.59.
This is a -1.67% slip from the previous day's closing price.
A total volume of 163,800 shares were traded at the close of the day’s session.
In the last one week, shares of Celularity Inc have slipped by -4.23%.
Celularity Inc's Key Ratios
Celularity Inc has a market cap of $90.60 million, indicating a price to book ratio of 1.3244 and a price to sales ratio of 11.6308.
In the last 12-months Celularity Inc’s revenue was $18.70 million with a gross profit of $11.68 million and an EBITDA of $-132655000. The EBITDA ratio measures Celularity Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Celularity Inc’s operating margin was -760.66% while its return on assets stood at -20.08% with a return of equity of -10.97%.
In Q3, Celularity Inc’s quarterly earnings growth was a negative -92.5% while revenue growth was a negative 61.1%.
Celularity Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 1.3091
- PEG
Its diluted EPS in the last 12-months stands at $0.45 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Celularity Inc’s profitability.
Celularity Inc stock is trading at a EV to sales ratio of 12.9421 and a EV to EBITDA ratio of -62.0623. Its price to sales ratio in the trailing 12-months stood at 11.6308.
Celularity Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $437.12 million
- Total Liabilities
- $69.22 million
- Operating Cash Flow
- $-1563000.00
- Capital Expenditure
- $1.56 million
- Dividend Payout Ratio
- 0%
Celularity Inc ended 2023 with $437.12 million in total assets and $0 in total liabilities. Its intangible assets were valued at $437.12 million while shareholder equity stood at $164.24 million.
Celularity Inc ended 2023 with $10000.00 in deferred long-term liabilities, $69.22 million in other current liabilities, 14000.00 in common stock, $-669930000.00 in retained earnings and $123.30 million in goodwill. Its cash balance stood at $42.65 million and cash and short-term investments were $42.65 million. The company’s total short-term debt was $39,255,000 while long-term debt stood at $0.
Celularity Inc’s total current assets stands at $63.10 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $4.45 million compared to accounts payable of $9.22 million and inventory worth $5.24 million.
In 2023, Celularity Inc's operating cash flow was $-1563000.00 while its capital expenditure stood at $1.56 million.
Comparatively, Celularity Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $0.59
- 52-Week High
- $13.186
- 52-Week Low
- $0.567
- Analyst Target Price
- $8.1
Celularity Inc stock is currently trading at $0.59 per share. It touched a 52-week high of $13.186 and a 52-week low of $13.186. Analysts tracking the stock have a 12-month average target price of $8.1.
Its 50-day moving average was $0.8 and 200-day moving average was $2.11 The short ratio stood at 5.45 indicating a short percent outstanding of 0%.
Around 6147.3% of the company’s stock are held by insiders while 2281.9% are held by institutions.
Frequently Asked Questions About Celularity Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company’s lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn’s disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.